Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $60
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $62 to $60.
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $62 to $60.